Vorinostat information

Vorinostat
Clinical data
Pronunciation	/vɒˈrɪnoʊstæt/ vorr-IN-oh-stat
Trade names	Zolinza
AHFS/Drugs.com	Monograph
MedlinePlus	a607050
License data	US FDA: Vorinostat;
Routes of; administration	Oral (capsules)
ATC code	L01XH01 (WHO) ;
Legal status
Legal status	US: ℞-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	1.8–11%
Protein binding	~71%
Metabolism	Hepatic glucuronidation and β-oxidation; CYP system not involved
Metabolites	vorinostat O-glucuronide, 4-anilino-4-oxobutanoic acid (both inactive)
Elimination half-life	~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid)
Excretion	Renal (negligible)
Identifiers
	IUPAC name N-Hydroxy-N'-phenyloctanediamide;
CAS Number	149647-78-9 ;
PubChem CID	5311;
IUPHAR/BPS	6852;
DrugBank	DB02546 ;
ChemSpider	5120 ;
UNII	58IFB293JI;
KEGG	D06320 ;
ChEBI	CHEBI:45716 ;
ChEMBL	ChEMBL98 ;
CompTox Dashboard (EPA)	DTXSID6041133 ;
ECHA InfoCard	100.207.822
Chemical and physical data
Formula	C14H20N2O3
Molar mass	264.325 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc1ccccc1)CCCCCCC(=O)NO;
	InChI InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) ; Key:WAEXFXRVDQXREF-UHFFFAOYSA-N ;
	(what is this?) (verify)

Vorinostat (rINN),^[3] also known as suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA), is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.

Vorinostat is marketed under the name Zolinza (/zoʊˈlɪnzə/ zoh-LIN-zə) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies.^[2]^[4] The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks.^[5]^[6]

^ "Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat)" (PDF). European Medicines Agency. 23 October 2008. p. 9. Archived from the original (PDF) on 15 September 2016. Retrieved 1 September 2016.
^ ^a ^b "Zolinza (vorinostat) Capsules. Full Prescribing Information" (PDF). Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Retrieved 1 September 2016.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56" (PDF). WHO Drug Information. 20 (3): 232. 2006. Archived from the original (PDF) on July 5, 2011. Retrieved 1 September 2016.
^ "ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration" (Press release). Merck & Co. June 7, 2006. Archived from the original on September 14, 2006. Retrieved October 6, 2006.
^ Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.
^ Marks PA, Breslow R (January 2007). "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407. S2CID 12656582.

[1] "Withdrawal Assessment Report for Vorinostat MSD 100 mg Hard Capsules (vorinostat)" (PDF). European Medicines Agency. 23 October 2008. p. 9. Archived from the original (PDF) on 15 September 2016. Retrieved 1 September 2016.

[Zolinza_PI-2] "Zolinza (vorinostat) Capsules. Full Prescribing Information" (PDF). Merck & Co., Inc., Whitehouse Station, NJ 08889, USA. Retrieved 1 September 2016.

[3] "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 56" (PDF). WHO Drug Information. 20 (3): 232. 2006. Archived from the original (PDF) on July 5, 2011. Retrieved 1 September 2016.

[4] "ZOLINZA, Merck's Investigational Medicine for Advanced Cutaneous T-Cell Lymphoma (CTCL), To Receive Priority Review from U.S. Food and Drug Administration" (Press release). Merck & Co. June 7, 2006. Archived from the original on September 14, 2006. Retrieved October 6, 2006.

[5] Lee JH, Mahendran A, Yao Y, Ngo L, Venta-Perez G, Choy ML, et al. (September 2013). "Development of a histone deacetylase 6 inhibitor and its biological effects". Proceedings of the National Academy of Sciences of the United States of America. 110 (39): 15704–15709. Bibcode:2013PNAS..11015704L. doi:10.1073/pnas.1313893110. PMC 3785767. PMID 24023063.

[:0-6] Marks PA, Breslow R (January 2007). "Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug". Nature Biotechnology. 25 (1): 84–90. doi:10.1038/nbt1272. PMID 17211407. S2CID 12656582.

Vorinostat information

and 24 Related for: Vorinostat information

Vorinostat

Histone deacetylase inhibitor

Disulfiram

Trichostatin A

Chromatin remodeling

Ketone bodies

Nicotinamide

Histone acetylation and deacetylation

Tretinoin

Methotrexate

Mycosis fungoides

Capsaicin

Curcumin

Hydroxycarbamide

Valproate

Sulforaphane

Abemaciclib

Celecoxib

Butyric acid

Histone deacetylase

Acute promyelocytic leukemia

Nitrogen mustard

Tisagenlecleucel

Mitomycin C

Clinical data

Pronunciation	/vɒˈrɪnoʊstæt/ vorr-IN-oh-stat
Trade names	Zolinza
AHFS/Drugs.com	Monograph
MedlinePlus	a607050
License data	US FDA: Vorinostat
Routes of administration	Oral (capsules)
ATC code	L01XH01 (WHO)
Legal status
Legal status	US: ℞-only In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	1.8–11%^[1]
Protein binding	~71%
Metabolism	Hepatic glucuronidation and β-oxidation CYP system not involved
Metabolites	vorinostat O-glucuronide, 4-anilino-4-oxobutanoic acid (both inactive)^[2]
Elimination half-life	~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid)
Excretion	Renal (negligible)
Identifiers
IUPAC name N-Hydroxy-N'-phenyloctanediamide
CAS Number	149647-78-9^Y
PubChem CID	5311
IUPHAR/BPS	6852
DrugBank	DB02546^Y
ChemSpider	5120^Y
UNII	58IFB293JI
KEGG	D06320^Y
ChEBI	CHEBI:45716^N
ChEMBL	ChEMBL98^Y
CompTox Dashboard (EPA)	DTXSID6041133
ECHA InfoCard	100.207.822
Chemical and physical data
Formula	C₁₄H₂₀N₂O₃
Molar mass	264.325 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C(Nc1ccccc1)CCCCCCC(=O)NO
InChI InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)^Y Key:WAEXFXRVDQXREF-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)